To provide an update on the genetic factors recently associated with the interindividual variability of tomato carotenoid bioavailability.
INTRODUCTION
Tomatoes, whether consumed raw or processed, are an important component of many human diets. For example, in the US population, they constitute the second most consumed vegetable, only topped by potatoes [1] . Their consumption has been associated with a decreased risk to develop several chronic diseases, such as cardiovascular diseases [2 & ], certain types of cancers [3 & ] or age-related macular degeneration [4 & ]. Tomatoes contain many potential health promoting compounds, for example minerals, vitamins or phytochemicals such as polyphenols and carotenoids [5] . Among these components, carotenoids have received considerable interest and results from many in vitro, animal, clinical and association studies point at their significant contribution to the observed health benefits of tomato consumption (see [6] for review). Carotenoids have been assumed to exert their biological effects through their well characterized antioxidant properties [7] or provitamin A activities for some (mainly b-carotene, a-carotene and b-cryptoxanthin).
However, it is now established that carotenoids, as parent molecules or via the many metabolites they can generate [8, 9] , also exhibit biological activities independent of their antioxidant properties, for example as modulators of inflammation [10, 11] or nuclear receptor ligands [12 & ,13] . Lycopene is the carotenoid found at the highest concentration in tomatoes, giving them their usual red colour, but other carotenoids are also found in significant amounts, that is a-carotene, b-carotene, d-carotene, g-carotene, lutein, and the colourless carotenoids ], is highly variable, depending on factors such as cultivar, environment, agronomic practices, stage of ripeness, or conditioning, which might in turn also modify the related health properties. Carotenoid concentration at their site of action in the human body depends on both their intake and their bioavailability. Carotenoid bioavailability is a complex phenotype, involving many steps and, as a consequence, it is highly variable. Indeed, many factors are involved, from characteristics of the diet, for example amount of fat, of fibres, food processing, to host-related features, for example sex, age, disease status or genetic characteristics [16, 17] . The early observation of a relatively high interindividual variability in b-carotene bioavailability [18] together with the more recent identification of several proteins involved in the intestinal absorption of carotenoids [17] has led to hypothesize that genetic variations in these genes could partly explain this variability. This field of research has lately received an increased interest, due to the emergence of affordable genotyping technologies, and several single nucleotide polymorphisms (SNPs) have been shown to be associated with the variability of tomato carotenoid bioavailability, opening the possibility for more personalized dietary recommendations that would improve the health benefits of tomato consumption.
PROTEINS INVOLVED IN TOMATO CAROTENOID BIOAVAILABILITY
Before discussing the genetic variations that have been associated with tomato carotenoid bioavailability, it is important to describe the successive steps involved, from their extraction from the food matrix during digestion to their distribution to their site of action, with an emphasis on the proteins implicated. Detailed descriptions can be found in several recent reviews [16, 17, 19] and we will here only focus on the more recent developments in this field. Carotenoids are lipids and their fate in the gastrointestinal tract during digestion, their absorption by enterocytes and their distribution in the circulation hence share common mechanisms with other lipid molecules, such as fat-soluble vitamins.
The first step involved in carotenoid bioavailability is their micellization, that is their transfer from the food matrix to mixed micelles. Digestive enzymes participate in this process by contributing to the degradation of the food matrix and indeed, pancreatic lipase, encoded by PNLIP, has been shown to facilitate the transfer of carotenoids from emulsified lipid droplets towards mixed micelles [20] . It should be emphasized that the efficiency of this process is relatively low, especially for lycopene where bioaccessibility values, that is percentage of incorporation in micelles, reported are typically 2% or less [21] , and that consequently, a large fraction of ingested carotenoids are not absorbed in the small intestine. They hence reach the colon but data regarding interaction with the gut microbiota is missing [22] and the fate of metabolites that could be produced remains largely unknown.
The second step is the uptake of bioaccessible carotenoids by enterocytes. Several proteins located at the apical membrane, at least temporarily, have been shown to participate in the facilitated diffusion of carotenoids: scavenger receptor class B member 1 (SR-BI), which is encoded by SCARB1, participates in the uptake of provitamin A carotenoids [23, 24] , lutein [25] , zeaxanthin [26 && ], lycopene [27] , phytoene and phytofluene [28] . CD36 molecule (CD36) facilitates provitamin A carotenoid uptake [23] and could also facilitate lycopene uptake [29] while NPC1 like intracellular cholesterol transporter 1 could be involved in the uptake of lutein [30] . Some of these proteins might actually interact indirectly with carotenoid uptake by promoting the assembly and secretion of chylomicrons, thereby increasing carotenoid gradient between the intestinal lumen and the enterocyte [31 & ,32] . Following their apical uptake, carotenoids can be metabolized by two enzymes, b-carotene oxygenase 1 (BCO1) [33] and b-carotene oxygenase 2 (BCO2) [34] , which differ in their substrates, products and cellular localization. BCO1 is a cytosolic enzyme which catalyses the oxidative central cleavage of provitamin A carotenoids, yielding at least one retinal molecules (two for b-carotene), but also that of beta-apocarotenals and lycopene [35] . BCO2 is a mitochondrial inner membrane protein which cleaves carotenoids eccentrically and yields apo-carotenals. Overall, BCO1 is assumed to be the main
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Tomato carotenoid bioavailability is highly variable and some of this variability is due to genetic differences between individuals.
Many proteins are involved in the bioavailability of carotenoids and their metabolites.
Several SNPs in the genes encoding these proteins have been associated with the observed interindividual variability in tomato carotenoid bioavailability.
More studies are needed to predict individual responses to tomato carotenoids and provide personalized dietary recommendations.
cleaving enzyme for provitamin A carotenoids while BCO2 is assumed to favour that of nonprovitamin A carotenoids [36 & ]. Nevertheless, this does not apply to lycopene as its cleavage seems to depend on its isomerization, which mostly takes place in the enterocyte [37] . Indeed, the all-trans isomer has been shown to be only cleaved by BCO1 [35, 38 & ], whereas the 5-cis and 13-cis isomers are only cleaved by BCO2 [39, 40] . These two enzymes are not solely expressed in enterocytes but it has been shown that more than 70% b-carotene conversion occurs in the small intestine [41] . Significantly, both BCO1 and SCARB1 are under the regulation of an intestinal transcription factor named intestine-specific homeobox (ISX): when cellular all-trans retinoic acid concentration increases, ISX is activated and in turns represses BCO1 and SCARB1 expression, which decreases carotenoid uptake and processing and ultimately retinoic acid production, thus constituting a negative feedback loop regulation of intracellular retinoic acid concentration [26 && ]. Significantly, a SNP in the ISX binding site in the BCO1 promoter was found to be associated with decreased conversion rates of b-carotene by 50% and increased fasting blood concentrations of b-carotene [42] . Although this mechanism was first described for b-carotene [43] , which yields two retinal molecules upon BCO1 cleavage, it has also been demonstrated for zeaxanthin [26 && ], a xanthophyll, and probably applies to other carotenoids. Overall, these proteins play crucial roles in carotenoid absorption and thus genetic variations in their encoding genes are good candidates to explain the high interindividual variability in carotenoid bioavailability. Moreover, we hypothesize that these genetic variations could also influence the profile of carotenoid metabolites generated upon carotenoid intake and hence modify some of their health properties, but this remains to be demonstrated.
To reach the circulation, carotenoids, or their metabolites, must be secreted at the basolateral side of the enterocyte. No intracellular transport protein has been identified yet, so the mechanism by which the parent molecules, which are highly apolar, as well as some of the more apolar metabolites, cross the enterocyte cytosol remains unknown. Native carotenoids are assumed to be mostly secreted with chylomicrons into the lymph. This process likely involves enzymes/apolipoproteins responsible for the assembly of chylomicrons, for example microsomal triglyceride transfer protein (MTP), apoA-IV, secretion associated Ras-related GTPase 1B (SAR1B) and apoB48 (encoded by APOB) [44] . Nevertheless, secretion in intestinal HDL via the ATP binding cassette A1 (ABCA1) has also been hypothesized [45] . On the other hands, some of the more polar metabolites (with log P values <5) may be secreted to the portal vein and then reach the liver.
Carotenoids secreted in chylomicrons are taken up by the liver via the chylomicron-remnant receptors, that is the LDL-receptor (LDLR), the LDLRrelated protein 1 and the heparan sulfate proteoglycans [46] . The fate of carotenoid metabolites secreted in the portal vein has yet to be studied. Carotenoids that reach the liver via chylomicrons are stored in this organ, eliminated in the bile or resecreted into VLDL to be distributed to peripheral tissues. However, it cannot be excluded that a fraction of carotenoids are able to significantly transfer between lipoproteins or to transfer from lipoproteins to tissues during intravascular chylomicron metabolism [47] . Xanthophylls are less apolar than carotenes and are thus found closer to the outer layer of lipoproteins compared with carotenes, thereby facilitating their potential exchange between lipoproteins. In agreement, recent data have shown that xanthophylls are transported mostly in HDL while carotenes are found preferentially in LDL, which result from VLDL metabolism [48 && ].
Regarding further carotenoid distribution, it has been hypothesized that only tissues that express the LDLR can take up carotenoids incorporated into LDL. Nonetheless, it has been shown that CD36, which is able to bind oxidized LDL, is involved in adipose tissue uptake of lycopene and lutein [29] , and that SR-BI, which is found in many tissues, is involved in the uptake of zeaxanthin into the retina. Indeed, it has recently been proposed that HDLzeaxanthin uptake into the retina is facilitated by SR-BI while that of LDL-lutein is facilitated by the LDL receptor [48 && ], thereby protecting the macula from light-induced damages [49,50 & ].
GENETIC VARIATIONS ASSOCIATED WITH TOMATO CAROTENOID BIOAVAILABILITY
Many clinical trials have investigated the interindividual variability in the response to carotenoid intake. Although there were many differences in the study designs (food vs. supplement, carotenoid dose ingested, measurement of carotenoid concentration in tissue vs. blood, number and characteristics of participants), they systematically reported a high interindividual variability in carotenoid bioavailability, including with tomato products as a source for carotenoids (see [16] for review).
Genetic variations between individuals have been suggested to explain, at least in part, this phenomenon [16, 17, 51, 52] . Consequently, several studies have aimed to identify genetic variants involved in the variability of the bioavailability of carotenoids (refer to Table 1 and Fig. 1 for summary of published studies). Several different approaches have been used to estimate carotenoid bioavailability [53] , which might yield different results depending on the relative contribution of the proteins involved. We have thus proposed to use the postprandial chylomicron carotenoid concentration as an estimate of carotenoid bioavailability to allow for comparison between studies [53] .
GENETIC VARIATIONS ASSOCIATED WITH LYCOPENE BIOAVAILABILITY
There are only two studies dedicated to identify genetic variations associated with lycopene bioavailability, using either watermelon juices or tomato puree as a source of lycopene. The first one investigated the association between two nonsynonymous SNPs in BCO1 and the plasma lycopene concentration in 23 healthy adults following the consumption of watermelon juices (representing 20-mg lycopene per day) for 3 weeks but no significant association was observed [54] . The second study sought to identify a combination of SNPs associated with tomato lycopene bioavailability, which was estimated by measuring the postprandial chylomicron lycopene response to a test-meal containing tomato puree (representing 9.7 mg all-trans lycopene) in 33 healthy male participants [55] . This study showed that lycopene bioavailability was associated with a combination of 28 SNPs in or near 16 candidate genes. Seven of these genes [ABCA1, lipoprotein lipase, insulin-induced gene 2, solute carrier family 27 member 6, hepatic lipase (LIPC), CD36 and APOB] had been associated with the postprandial chylomicron triacylglycerol response in the same group of participants [56] . Four of these genes were more specifically associated with the variability in lycopene bioavailability. ABCB1 encodes for the P-glycoprotein, an ATP-dependent drug efflux pump for xenobiotics with broad substrate specificity, highly expressed in enterocytes. The association of P-glycoprotein with postprandial lycopene concentrations suggests that it could participate in the efflux of lycopene back to the intestinal lumen, as was recently shown for vitamin D [57] . ELOVL2 encodes for ELOVL fatty acid (FA) elongase 2 which catalyzes the elongation of eicosapentaenoic acid to docosapentaenoic acid and docosapentaenoic acid to docosahexaenoic acid. Carotenoids are not known substrates for this enzyme but this association could be due to an interaction between omega 3 FA metabolism and carotenoids as eicosapentaenoic acid has been shown to inhibit b-carotene absorption [58 
GENETIC VARIATIONS ASSOCIATED WITH LUTEIN BIOAVAILABILITY
There are only two studies dedicated to identify genetic variations associated with lutein bioavailability. Neither used tomatoes or tomato products as a source of lutein since other food sources, for example spinach, provide higher amounts thereof. In the first one, Yonova-Doing et al. [60] measured macular pigment optical density (OD), which is a marker of lutein and zeaxanthin concentration in the macula, in 310 white female twins aged 20-50 before and after receiving 54-mg lutein and 7.2-mg zeaxanthin daily for 6 months. They found four SNPs to be significantly associated with the change in macular pigment OD following supplementation, which can be considered as a marker of xanthophyll bioavailability: a SNP in ABCA1, possibly due to the role of this membrane protein in lipid influx in the retinal pigment epithelium [61] and/or to enterocyte basolateral secretion of HDL-lutein [45] , a SNP in SCARB1, a SNP in fatty acid desaturase 1 and a SNP in retinal pigment epithelium 65. FA desaturase 1 is involved in the conversion of a-linolenic acid to eicosapentaenoic acid, which again suggests an association between omega 3 FA metabolism and carotenoid bioavailability. Retinal pigment epithelium 65 encodes a protein highly expressed in the retinal pigment epithelium, working as a retinol isomerase of the visual cycle, which is involved in visual pigment regeneration and was recently shown to be responsible for the macular production of mesozeaxanthin from lutein [62 & ]. In the second study, the variability in the postprandial chylomicron lutein response to a test-meal supplemented with 15 mg free lutein was associated with a combination of 29 SNPs in 15 genes in a group of 39 healthy adult men [63] . Nine of these genes (ABCA1, APOA1, APOB, cordon-bleu WH2 repeat protein like 1, hepatic lipase, insulin-induced gene 2, insulin receptor substrate 1, lipoprotein lipase and melanocortin 4 receptor) were previously associated with the interindividual variability in the postprandial chylomicron triglyceride response in the same group of participants (39) . Four genes were more specifically associated with lutein bioavailability: ATP-binding cassette, subfamily G, member 2, ELOVL2, ISX and MTTP. Significantly, b These SNPs were associated with the variability of carotenoid bioavailability, but this was likely due to their association with the variability of the chylomicron triacylglycerol response [56] . SNP, single nucleotide polymorphism.
SNPs in the last three genes were also associated with lycopene variability. ATP-binding cassette, subfamily G, member 2 encodes for a breast cancer resistance protein, which is a multidrug transporter [64] , and this association suggests it could also be involved in lutein transport.
GENETIC VARIATIONS ASSOCIATED WITH BETA-CAROTENE BIOAVAILABILITY
There have been four studies, based on three different trials, investigating the effects of genetic variants on b-carotene bioavailability, although only one used tomato puree as a source, whereas the others used either a supplement or watermelon juices. Two common nonsynonymous SNPs in BCO1 have been associated with the postprandial triglyceride-rich lipoprotein b-carotene and retinyl palmitate concentrations following consumption of a meal supplemented with 120-mg b-carotene [65] . The same two SNPs were also associated with blood b-carotene concentration following consumption for 3 weeks of a watermelon juice, providing a more nutritional dose of b-carotene (2.5 mg/day) [54] . In a reanalysis of the first trial, three SNPs upstream from BCO1 were associated with b-carotene conversion capacity [66] . In the most recent study, the variability in the postprandial chylomicron b-carotene response to a test-meal containing 100-g tomato puree, providing 0.4-mg b-carotene, was associated with a combination of 25 SNPs in 12 genes [67] . Four genes (ABCA1, APOB, hepatic lipase, transcription factor 7-like 2) were previously associated with the interindividual variability in the postprandial chylomicron triglyceride response in the same group of participants [56] , whereas eight were more specifically associated with the b-carotene response. Significantly, a SNP in ISX and a SNP in BCO1 were identified, thereby confirming the key role played by ISX in b-carotene bioavailability [42] . Moreover, it should be stressed that the same SNP in ELOVL2 that was associated with the variability of lycopene 
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Non-absorbed carotenoids FIGURE 1. Summary of the genes involved in the variability of tomato carotenoid bioavailability. Genes displayed are those for which SNPs have been associated with the variability of the bioavailability of lycopene, b-carotene or lutein. Genes in bold letters are those for which SNPs have been associated with the variability of the bioavailability of these three carotenoids. SNP, single nucleotide polymorphism.
and lutein bioavailability was associated with b-carotene bioavailability. Overall, six genes (ABCA1, APOB, ELOVL2, ISX, LIPC and polycystin 1 like 2) have been consistently shown to have SNPs associated with the variability in the bioavailability of b-carotene, lutein and lycopene, and in particular the same SNP in ELOVL2 across all three carotenoids. Furthermore, these results were obtained in the same group of participants [55, 63, 67] .
Although it appears that for some of the associations reported, tomatoes or tomato products were not used as a source of carotenoids, we believe these results can be extrapolated to tomatoes or tomato products because the main source of variability in these clinical trials originates from genetic variations. Nonetheless, if the effect of the food matrix on carotenoid bioavailability were to be high, it could potentially not allow the comparison with tomatoes or tomato products.
CONCLUSION
Several genetic variants have now been involved in the variability of the bioavailability of the major carotenoids found in tomatoes and they could explain to some extent the variability observed in the health effects associated with tomato and tomato product consumption. Yet, some carotenoids found in significant amount in tomato and tomato products, such as phytoene and phytofluene, have been completely left out of studies so far although they might also be associated with the health properties of tomatoes and tomato products. We now need clinical studies with more participants (including more ethnic groups) to confirm these promising results. More SNPs/genes should be investigated and other genetic variations (e.g. copy number variants) or epigenetic modifications should also be considered. To date, there is no data on the effects of genetic variations on the production and bioavailability of carotenoid metabolites, which could be responsible for some of the health effects conferred by tomatoes. Although a lot of work remains to be done, this field of research is promising, and the results generated will contribute to provide more personalized dietary recommendations to improve the benefits of tomato consumption.
